JNJ-67484703 for Rheumatoid Arthritis

"This medical study is looking to recruit 47 individuals, aged between 18 and 65, who have been diagnosed with rheumatoid arthritis. Moreover, applicants must have already demonstrated an insufficient response or tolerance to at least one conventional synthetic DMARD (csDMARD) and/or up two biologic/targeted syntheric DMARDS (bDMARDs/tsMDARDS). Additionally participants need a CRP of 0.3 mg/dL or above at screening; their vital signs should be medically sound as per physical examination, medical history and 12-lead ECG taken at the same time. Furthermore only those whose body weight falls in"

"Clinicaltrials.gov indicates that recruitment for this experiment is still in process, having begun on October 18th 2021 and last modified November 22nd 2022."

"There is sparse data available that supports JNJ-67484703's efficacy and safety, which has resulted in it being awarded a score of 1."

"The primary measure of success for this clinical trial, which is planned to last up to 24 weeks, will be the percentage of participants with treatment-emergent serious adverse events (SAEs). Secondary objectives include assessing changes in patients' Disease Activity Index Score 28 using C-reactive Protein (DAS28-CRP) at Week 12. This score combines evaluations from 28 joints across both upper and lower extremities. A DAS28-CRP value below 3.2 indicates best disease control whereas a score above 5.1 suggests worse management outcomes. Additionally, researchers are planning on recording percentages of study subjects who have developed antibodies"

"This study's inclusion criteria requires patients to be aged between 18-65. Individuals younger than this age bracket have a total of 51 trials they can enrol in, while those 65 and above are presented with 329 different studies."

"Affirmative, the clinicaltrials.gov database confirms that this investigation is currently recruiting participants. The trial first appeared on October 18th 2021 and was most recently modified on November 22nd 2022. There are 47 total expected enrollees from 2 medical centres."